News articles for Decision Resources:
Thursday, February 9, 2012
Thursday, February 2, 2012
Wednesday, February 1, 2012
Surveyed U.S. Endocrinologists Indicate They Would Prescribe Amylin/Alkermes’ Bydureon to 20 Percent of Their Patients with Type 2 Diabetes
Decision Resources, one of the world’s leading research and advisory
firms for pharmaceutical and healthcare issues, finds that surveyed U.S.
endocrinologists indicate that they would prescribe Amylin/Alkermes’
...
read moreMonday, January 23, 2012
Thursday, December 22, 2011
Wednesday, December 21, 2011
Monday, December 19, 2011
Wednesday, December 14, 2011
Tuesday, December 13, 2011
Moderate Growth in the Crohn’s Disease Drug Market Will Mask Dramatic Changes as Sales of Newer and Emerging Agents Will Outpace the Decline in Sales of Older, Established Agents
Decision Resources, one of the world’s leading research and advisory
firms for pharmaceutical and healthcare issues, finds that, from 2010 to
2020, the Crohn’s disease drug market will ...
read moreMonday, December 12, 2011
Through 2020, Generic Erosion of Blockbuster Agents Will Be a Major Contributor to a Nearly $6 Billion Decrease in the Dyslipidemia Drug Market
Decision Resources, one of the world’s leading research and advisory
firms for pharmaceutical and healthcare issues, finds that, through
2020, the generic erosion of blockbuster agents—most notably Pfizer’s ...
read moreThe Combined Markets for Drugs Used in the Treatment and Prophylaxis of Venous Thromboembolism Will Increase from $3.4 Billion in 2010 to $4.7 Billion in 2020
Decision Resources, one of the world’s leading research and advisory
firms for pharmaceutical and healthcare issues, finds that, driven
primarily by the launches and strong uptake of oral ...
read moreThursday, December 8, 2011
Through 2020, the Asthma Drug Market Will Remain Flat Amidst Generic Erosion of Key Agents and Increased Product Competition
Decision Resources, one of the world’s leading research and advisory
firms for pharmaceutical and healthcare issues, finds that, despite the
uptake of high-price once-daily combinations and novel anticytokine ...
read moreWednesday, December 7, 2011
Tuesday, December 6, 2011
Wednesday, November 30, 2011